Autologous fibroblast therapy for facial rejuvenation: A randomized open-label controlled study

IF 1.8 Q3 SURGERY

JPRAS Open Pub Date : 2026-07-01 Epub Date: 2026-06-01 DOI:10.1016/j.jpra.2026.05.045

Pietro Gentile

{"title":"Autologous fibroblast therapy for facial rejuvenation: A randomized open-label controlled study","authors":"Pietro Gentile","doi":"10.1016/j.jpra.2026.05.045","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The aging process of the face is characterized by dermal thinning, loss of elasticity, and wrinkle formation. Injection of autologous micrografts containing fibroblasts (Am-FBs) has emerged as a promising regenerative technique.</div></div><div><h3>Objectives</h3><div>This trial aims to assess the efficacy and safety of Am-FBs for facial rejuvenation.</div></div><div><h3>Methods</h3><div>A randomized, open-label, controlled study was conducted. Forty patients presenting with mild to moderate dermal thinning, reduced elasticity, and wrinkles were divided into two groups: a study group (SG; n = 20) that received Am-FBs treatment and a control group (CG; n = 20) treated with a hyaluronic acid (HA)–based skin booster. Both groups received treatment at baseline (T0), at one month (T1), and at three months (T2). Clinical outcomes were evaluated at T1, T2, T3 (6 months), and T4 (12 months) through patient and physician evaluations, the Wrinkle Severity Rating Scale (WSRS), and objective skin elasticity metrics. <em>In vitro</em> evaluation of the Am-FBs and immunophenotypic characterization of the nucleated cell population contained in the Am-FBs suspension was performed.</div></div><div><h3>Results</h3><div>At T4, the SG showed significantly greater improvements in wrinkle depth, skin elasticity, and WSRS score than the CG (<em>p</em> < 0.01). The physician’s evaluation showed scores ranging from 9 to 4 (<em>p</em> = 0.049), whereas patient self-assessments ranged from 9 to 5 (<em>p</em> = 0.039). Patient satisfaction was higher in the SG. The in vitro analysis documented 2.780.750 nucleated cells/ml in Am-FBs with a viability of 89.61% and immunophenotype: CD34%0.2, CD45%0.2, CD44%98.7, CD200%80.0, Cytokeratin 15%99.4.</div></div><div><h3>Conclusions</h3><div>Am-FBs significantly improve signs of facial aging and present a safe option for skin rejuvenation.</div></div>","PeriodicalId":37996,"journal":{"name":"JPRAS Open","volume":"50 ","pages":"Pages 632-644"},"PeriodicalIF":1.8000,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13285675/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JPRAS Open","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S235258782600207X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/6/1 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The aging process of the face is characterized by dermal thinning, loss of elasticity, and wrinkle formation. Injection of autologous micrografts containing fibroblasts (Am-FBs) has emerged as a promising regenerative technique.

Objectives

This trial aims to assess the efficacy and safety of Am-FBs for facial rejuvenation.

Methods

A randomized, open-label, controlled study was conducted. Forty patients presenting with mild to moderate dermal thinning, reduced elasticity, and wrinkles were divided into two groups: a study group (SG; n = 20) that received Am-FBs treatment and a control group (CG; n = 20) treated with a hyaluronic acid (HA)–based skin booster. Both groups received treatment at baseline (T0), at one month (T1), and at three months (T2). Clinical outcomes were evaluated at T1, T2, T3 (6 months), and T4 (12 months) through patient and physician evaluations, the Wrinkle Severity Rating Scale (WSRS), and objective skin elasticity metrics. In vitro evaluation of the Am-FBs and immunophenotypic characterization of the nucleated cell population contained in the Am-FBs suspension was performed.

Results

At T4, the SG showed significantly greater improvements in wrinkle depth, skin elasticity, and WSRS score than the CG (p < 0.01). The physician’s evaluation showed scores ranging from 9 to 4 (p = 0.049), whereas patient self-assessments ranged from 9 to 5 (p = 0.039). Patient satisfaction was higher in the SG. The in vitro analysis documented 2.780.750 nucleated cells/ml in Am-FBs with a viability of 89.61% and immunophenotype: CD34%0.2, CD45%0.2, CD44%98.7, CD200%80.0, Cytokeratin 15%99.4.

Conclusions

Am-FBs significantly improve signs of facial aging and present a safe option for skin rejuvenation.

查看原文本刊更多论文

自体成纤维细胞治疗面部年轻化：一项随机开放标签对照研究。

背景：面部老化过程的特点是真皮变薄，失去弹性，皱纹形成。注射含有成纤维细胞的自体微移植物（Am-FBs）是一种很有前途的再生技术。目的：本试验旨在评估Am-FBs面部年轻化的有效性和安全性。方法：采用随机、开放标签、对照研究。40例出现轻度至中度皮肤变薄、弹性降低和皱纹的患者被分为两组：研究组（SG, n = 20）接受Am-FBs治疗，对照组（CG, n = 20）接受透明质酸（HA）皮肤增强剂治疗。两组均在基线（T0）、1个月（T1）和3个月（T2）时接受治疗。在T1、T2、T3（6个月）和T4（12个月）通过患者和医生评估、皱纹严重程度评定量表（WSRS）和客观皮肤弹性指标评估临床结果。对Am-FBs进行体外评价，并对Am-FBs悬浮液中含有的有核细胞群进行免疫表型表征。结果：T4时，SG组在皱纹深度、皮肤弹性、WSRS评分方面均显著优于CG组（p < 0.01）。医生的评分范围为9到4分（p = 0.049），而患者的自我评估范围为9到5分（p = 0.039）。SG组患者满意度较高。体外分析显示，Am-FBs中有核细胞2.780.750个/ml，存活率为89.61%，免疫表型为cd34% 0.2, cd45% 0.2, cd44% 98.7, cd200% 80.0, Cytokeratin 15%99.4。结论：Am-FBs显著改善面部衰老迹象，是皮肤年轻化的安全选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

JPRAS Open Medicine-Surgery

CiteScore

1.60

自引率

0.00%

发文量

审稿时长

22 weeks

期刊介绍： JPRAS Open is an international, open access journal dedicated to publishing case reports, short communications, and full-length articles. JPRAS Open will provide the most current source of information and references in plastic, reconstructive & aesthetic surgery. The Journal is based on the continued need to improve surgical care by providing highlights in general reconstructive surgery; cleft lip, palate and craniofacial surgery; head and neck surgery; skin cancer; breast surgery; hand surgery; lower limb trauma; burns; and aesthetic surgery. The Journal will provide authors with fast publication times.